BioRestorative Therapies, Inc. (BRTX)

Over the past six months, BioRestorative Therapies' stock has declined by 26.23%. Key events include the release of Q2 and Q3 2025 financial results, the award of a Japanese patent, and the closing of a registered direct offering. The company was granted an FDA Type B meeting to discuss a potential accelerated BLA approval pathway for BRTX-100. Short interest in BRTX increased in December 2025, and a stock buyback program was initiated in June 2025.

While there is a seasonal chart analysis for BRTX stock performance, the company's Q3 2025 financial results noted that a year-over-year decrease in biocosmeceutical revenue was primarily related to the specific timing of orders, suggesting that demand for this product line may experience lumpiness or specific ordering cycles rather than consistent seasonal patterns.

BioRestorative Therapies, Inc. is a clinical-stage biotechnology company in the Healthcare sector, focusing on regenerative medicine using adult stem cells. Its core business involves cell and tissue protocols, developing therapeutic products and medical therapies. The company's major product pipeline includes BRTX-100 for lumbosacral disc disorders and chronic lower back pain, currently in Phase 2 clinical trial with FDA Fast Track designation. Another key program is ThermoStem, a cell-based therapy targeting obesity and metabolic disorders. Additionally, BioRestorative Therapies operates a commercial biocosmeceutical platform and holds a license for an investigational curved needle device.

BioRestorative Therapies, Inc. is based in the United States and is headquartered in Melville, New York. The company was awarded a notice of allowance for a Japanese patent in October 2025, indicating an international intellectual property strategy.

BioRestorative Therapies' brand reputation has faced challenges, reflected by a consensus "Sell" rating and increasing short interest. However, the FDA granted Fast Track designation to its BRTX-100 program, which can be viewed positively.

BioRestorative Therapies, Inc. has a diverse ownership structure. Institutional shareholders hold between 4.28% and 69.38% of the stock, insiders hold between 17% and 1,153.65%, and the general public holds approximately 63.2% of the shares. Major institutional owners include Citadel Advisors Llc and Vanguard Group Inc. Significant individual and insider owners include Westbury Bermuda Ltd and Antonio Joel San.